Consistent with this hypothesis, our data demonstrated that SMARCA4/A2-deficient small cell cancer of the ovary hypercalcemia type (SCCOHT) and non-small cell lung cancer (NSCLC) models are acutely sensitive to BETi at low nanomolar concentrations in vitro as well as in vivo (20 mg/kg per day).88 Further support for this premise comes from the observation that ectopic expression of SMARCA4 was found to confer partial resistance to BETi. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.